Pharmaceutical Technology
SEPTEMBER 3, 2024
In clinical supplies, the Importer of Record (IoR) provides a critical service in facilitating logistics and easing the burden for sponsors.
Bio Pharma Dive
SEPTEMBER 3, 2024
While results from two after-the-fact analyses were “reassuring,” outside experts urged “continued vigilance” to ensure GLP-1 drugs don’t worsen problems in people with preexisting mental health conditions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 3, 2024
The UAE has partnered with Novo Nordisk Pharma Gulf to develop a national scientific guide for obesity management and weight control.
Bio Pharma Dive
SEPTEMBER 3, 2024
The company's value jumped by several billion dollars as trial results showed its experimental shot could match and, in some cases, even outperform Pfizer's market-leading Prevnar 20.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
SEPTEMBER 3, 2024
There are currently no approved treatments that can halt or reverse photoreceptor degeneration in patients with retinitis pigmentosa.
Bio Pharma Dive
SEPTEMBER 3, 2024
Tolebrutinib, which Sanofi acquired in a $3.7 billion deal, failed two studies in people with relapsing disease, but succeeded in a type of multiple sclerosis that has no approved therapies.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
SEPTEMBER 3, 2024
The Phase 2 results for Recursion’s cerebral cavernous malformation treatment are the first in a series of important trial readouts for the high-profile “techbio” company.
Pharmaceutical Technology
SEPTEMBER 3, 2024
Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.
Bio Pharma Dive
SEPTEMBER 3, 2024
Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.
Pharmaceutical Technology
SEPTEMBER 3, 2024
Simcere Zaiming has entered a collaboration deal with Shenzhen TargetRx to bring TGRX-326 to the Chinese market.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
SEPTEMBER 3, 2024
Following a recent listening session hosted by the agency, current and former members have weighed in on the process and how it could be improved.
Pharmaceutical Technology
SEPTEMBER 3, 2024
The UK NHS has commenced its first-ever vaccination programme for RSV vaccine, targeting pregnant women and older adults.
Bio Pharma Dive
SEPTEMBER 3, 2024
The sequencing firm will avoid a penalty of 432 million euros after a court ruled the European Commission did not have jurisdiction to challenge the company’s Grail acquisition.
Pharmaceutical Technology
SEPTEMBER 3, 2024
New data provides more evidence on choosing the ideal approach for prescription of beta blockers for myocardial infarction.
pharmaphorum
SEPTEMBER 3, 2024
EU had no grounds to probe Illumina's takeover of Grail, says ECJ, but while spinoff has already taken place Illumina can now avoid a €432m fine
Pharmaceutical Technology
SEPTEMBER 3, 2024
Syntekabio has entered a partnership with Enamine for supply, synthesis of compounds and synthetic drug development.
Pharmaceutical Commerce
SEPTEMBER 3, 2024
How can industry stakeholders ensure the quality and supply chain security of existing product?
pharmaphorum
SEPTEMBER 3, 2024
New data for Valneva and Pfizer's Lyme disease vaccine bolsters the case for the shot as the results of a phase 3 programme are awaited.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Outsourcing Pharma
SEPTEMBER 3, 2024
Dr Dawn Thompson has over 20 years of experience in building technology platforms that leverage genomics at scale to produce novel products.
Pharmaceutical Commerce
SEPTEMBER 3, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.
Drug Patent Watch
SEPTEMBER 3, 2024
Scaling your business with a Contract Development and Manufacturing Organization (CDMO) is crucial for biopharmaceutical companies seeking to expedite the transition from preclinical development to clinical manufacturing. CDMOs play a vital role in providing expertise in process development and scale-up manufacturing, allowing biotech companies to adapt to changing market dynamics and client needs.
Pharmaceutical Commerce
SEPTEMBER 3, 2024
The latest news for pharma industry insiders.
pharmaphorum
SEPTEMBER 3, 2024
A digital version of the NHS Health Check offered to older people in the UK will be piloted in some areas of England early next year, according to the government.The Department of Health and Social Care (DHSC) has said the digital alternative to the current system of in-person health checks will be ready for testing in early 2025, with pilots planned for Norfolk, Medway, and Lambeth in London.
Fierce Pharma
SEPTEMBER 3, 2024
Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. | The company and the European Medicines Agency warned European healthcare providers to continue limiting new patient prescriptions until the shortages let up.
pharmaphorum
SEPTEMBER 3, 2024
Discover the latest hiring news and updates in the pharma and biotech industry for August 2024, featuring companies like AstraZeneca, Pfizer, BioMarin, 4DMT and more. Stay informed about the changing faces of these leading organisations.
BioPharma Reporter
SEPTEMBER 3, 2024
The U.S. company Emergent BioSolutions recently announced the FDA approval of its application to expand the indication for ACAM2000 â previously approved for smallpox â to include the prevention of mpox in high-risk individuals.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
SEPTEMBER 3, 2024
EU follows through on plan to revoke approval for Advanz Pharma's Ocaliva for rare disease primary biliary cholangitis (PBC)
Fierce Pharma
SEPTEMBER 3, 2024
Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. | Semnur Pharmaceuticals is following in its parent company Scilex's footsteps with a special purpose acquisition company (SPAC) merger.
pharmaphorum
SEPTEMBER 3, 2024
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.Just-reported data from that study has shown that Vaxcyte's VAX-31 shot was able to stimulate a strong immune response against all 31 serotypes of Streptococcus pneumoniae included in the formulation, in adults aged 50 and over.
Fierce Pharma
SEPTEMBER 3, 2024
Dr. Reddy’s has been cut off from China’s bulk-buy drug procurement program after an inspection turned up “serious defects” in the company’s manufacturing operations. | Following a remote inspection of a Dr. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
260 
Let's personalize your content